Ramatroban

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ramatroban
Accession Number
DB13036
Type
Small Molecule
Groups
Investigational
Description

Ramatroban has been used in trials studying the treatment of Asthma.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
P1ALI72U6C
CAS number
116649-85-5
Weight
Average: 416.47
Monoisotopic: 416.120606501
Chemical Formula
C21H21FN2O4S
InChI Key
LDXDSHIEDAPSSA-OAHLLOKOSA-N
InChI
InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
IUPAC Name
3-[(3R)-3-(4-fluorobenzenesulfonamido)-2,3,4,9-tetrahydro-1H-carbazol-9-yl]propanoic acid
SMILES
[H][C@]1(CCC2=C(C1)C1=CC=CC=C1N2CCC(O)=O)NS(=O)(=O)C1=CC=C(F)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UProstaglandin D2 receptor 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabRamatroban may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolRamatroban may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ramatroban is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Ramatroban is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the antiplatelet activities of Ramatroban.Approved, Investigational
AlteplaseRamatroban may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Ramatroban is combined with Aminosalicylic Acid.Approved
AnagrelideRamatroban may increase the anticoagulant activities of Anagrelide.Approved
AncrodRamatroban may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Ramatroban.Investigational
AnistreplaseRamatroban may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanRamatroban may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Apixaban.Approved
ArdeparinRamatroban may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanRamatroban may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinRamatroban may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the antiplatelet activities of Ramatroban.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Ramatroban is combined with Balsalazide.Approved, Investigational
BatroxobinRamatroban may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminRamatroban may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinRamatroban may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostRamatroban may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinRamatroban may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseRamatroban may increase the anticoagulant activities of Brinase.Experimental
BuflomedilRamatroban may increase the antiplatelet activities of Buflomedil.Experimental
ButylphthalideButylphthalide may increase the antiplatelet activities of Ramatroban.Investigational
CangrelorRamatroban may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabRamatroban may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Ramatroban is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinRamatroban may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolRamatroban may increase the anticoagulant activities of Cilostazol.Approved, Investigational
Citric AcidRamatroban may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelRamatroban may increase the anticoagulant activities of Clopidogrel.Approved
CloricromenRamatroban may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneRamatroban may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Ramatroban is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateRamatroban may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinRamatroban may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidRamatroban may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanRamatroban may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Ramatroban.Approved, Investigational
DefibrotideRamatroban may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ramatroban is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Ramatroban is combined with Dersalazine.Investigational
DesirudinRamatroban may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseRamatroban may increase the anticoagulant activities of Desmoteplase.Investigational
DextranRamatroban may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolRamatroban may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Ramatroban is combined with Diflunisal.Approved, Investigational
DiphenadioneRamatroban may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleRamatroban may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleRamatroban may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaRamatroban may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidRamatroban may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanRamatroban may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinRamatroban may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Ramatroban.Approved, Investigational
EplivanserinRamatroban may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineRamatroban may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolRamatroban may increase the anticoagulant activities of Epoprostenol.Approved
EptifibatideRamatroban may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateRamatroban may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidRamatroban may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinRamatroban may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneRamatroban may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxRamatroban may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumRamatroban may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateRamatroban may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Ramatroban.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Ramatroban is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Ramatroban is combined with Hemoglobin crosfumaril.Experimental
HeparinRamatroban may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineRamatroban may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolHydroxytyrosol may increase the antiplatelet activities of Ramatroban.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ramatroban.Approved
IbudilastIbudilast may increase the antiplatelet activities of Ramatroban.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Ramatroban.Approved, Investigational, Nutraceutical
IdraparinuxRamatroban may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the antiplatelet activities of Ramatroban.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the antiplatelet activities of Ramatroban.Investigational
IloprostRamatroban may increase the anticoagulant activities of Iloprost.Approved, Investigational
IndobufenRamatroban may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the antiplatelet activities of Ramatroban.Investigational
LepirudinRamatroban may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanRamatroban may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostLimaprost may increase the antiplatelet activities of Ramatroban.Approved, Investigational
LinsidomineRamatroban may increase the antiplatelet activities of Linsidomine.Experimental
MelagatranRamatroban may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Ramatroban is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Ramatroban is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the antiplatelet activities of Ramatroban.Approved
NadroparinRamatroban may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatRamatroban may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the antiplatelet activities of Ramatroban.Investigational
NimesulideNimesulide may increase the antiplatelet activities of Ramatroban.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Ramatroban is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Ramatroban is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Ramatroban is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ramatroban.Approved, Nutraceutical
OtamixabanRamatroban may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelRamatroban may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinRamatroban may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateRamatroban may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ramatroban.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Ramatroban.Approved, Investigational
PhenindioneRamatroban may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonRamatroban may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Ramatroban is combined with Phenyl aminosalicylate.Approved
PicotamideRamatroban may increase the anticoagulant activities of Picotamide.Experimental
PrasugrelRamatroban may increase the anticoagulant activities of Prasugrel.Approved
Protein CRamatroban may increase the anticoagulant activities of Protein C.Approved
Protein S humanRamatroban may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeRamatroban may increase the anticoagulant activities of Protocatechualdehyde.Approved
RelcovaptanRamatroban may increase the antiplatelet activities of Relcovaptan.Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Ramatroban.Approved, Experimental, Investigational
ReteplaseRamatroban may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinRamatroban may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Ramatroban.Approved
RivaroxabanRamatroban may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneRamatroban may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Ramatroban is combined with Salicylic acid.Approved, Investigational, Vet Approved
SarpogrelateRamatroban may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseRamatroban may increase the anticoagulant activities of Saruplase.Experimental
SelexipagRamatroban may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Ramatroban.Approved, Vet Approved
SRT501SRT501 may increase the antiplatelet activities of Ramatroban.Investigational
StreptokinaseRamatroban may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideRamatroban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseRamatroban may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the antiplatelet activities of Ramatroban.Investigational
TicagrelorRamatroban may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineRamatroban may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinRamatroban may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolRamatroban may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Ramatroban.Approved, Investigational
TirofibanRamatroban may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ramatroban is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the antiplatelet activities of Ramatroban.Approved, Investigational
TrapidilTrapidil may increase the antiplatelet activities of Ramatroban.Approved
TreprostinilRamatroban may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalRamatroban may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Ramatroban is combined with Trolamine salicylate.Approved
TroxerutinRamatroban may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseRamatroban may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Ramatroban.Approved, Nutraceutical, Vet Approved
VorapaxarRamatroban may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinRamatroban may increase the anticoagulant activities of Warfarin.Approved
XimelagatranRamatroban may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
123879
PubChem Substance
347829169
ChemSpider
110413
BindingDB
50161746
ChEBI
32087
ChEMBL
CHEMBL361812
Wikipedia
Ramatroban

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3WithdrawnTreatmentAsthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0227 mg/mLALOGPS
logP2.3ALOGPS
logP3.3ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.39ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area88.4 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity107.08 m3·mol-1ChemAxon
Polarizability42.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Carbazoles
Direct Parent
Carbazoles
Alternative Parents
3-alkylindoles / Benzenesulfonamides / N-alkylindoles / Benzenesulfonyl compounds / Fluorobenzenes / Substituted pyrroles / Organosulfonamides / Aryl fluorides / Aminosulfonyl compounds / Heteroaromatic compounds
show 9 more
Substituents
Carbazole / Benzenesulfonamide / N-alkylindole / 3-alkylindole / Benzenesulfonyl group / Indole / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Sugimoto H, Shichijo M, Okano M, Bacon KB: CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses. Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. Epub 2005 Oct 27. [PubMed:16256979]

Drug created on October 20, 2016 20:16 / Updated on May 02, 2018 00:27